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Potent Prearranged Positive Allosteric Modulators of the
Glucagon-like Peptide-1 Receptor
Ben J. Jones,[a] Rosario Scopelliti,[b] Alejandra Tomas,[c] Stephen R. Bloom,[a] David J. Hodson,*[d, e] and
Johannes Broichhagen*[b, f]
Drugs that allosterically modulate G protein-coupled receptor
(GPCR) activity display higher specificity and may improve dis-
ease treatment. However, the rational design of compounds
that target the allosteric site is difficult, as conformations re-
quired for receptor activation are poorly understood. Guided
by photopharmacology, a set of prearranged positive allosteric
modulators (PAMs) with restricted degrees of freedom was de-
signed and tested against the glucagon-like peptide-1 receptor
(GLP-1R), a GPCR involved in glucose homeostasis. Compounds
incorporating a trans-stilbene comprehensively outperformed
those with a cis-stilbene, as well as the benchmark BETP, as
GLP-1R PAMs. We also identified major effects of ligand confor-
mation on GLP-1R binding kinetics and signal bias. Thus, we
describe a photopharmacology-directed approach for rational
drug design, and introduce a new class of stilbene-containing
PAM for the specific regulation of GPCR activity.
G protein-coupled receptors (GPCRs) are critical for organism
homeostasis by converting signals encoded by extracellular
molecules into an appropriate cell response.[1] Classically, li-
gands bind the extracellularly located orthosteric face of the
GPCR, leading to conformational changes and activation of
second messenger pathways.[1] GPCRs are also subject to allo-
steric regulation, whereby small molecular entities influence or-
thosteric activation.[2] Such allosteric modulators are therapeut-
ically desirable, as they demonstrate excellent specificity and
selectivity.[2a]
Recently, we described allosteric optical control of the gluca-
gon-like peptide-1 receptor (GLP-1R),[3] a prototypical class B
GPCR involved in the maintenance of blood glucose levels and
a blockbuster target for type 2 diabetes treatment.[4] As pep-
tide ligands that target the GLP-1R must be injected, the de-
velopment of orally available small-molecule GLP-1R activators
is a priority. In our previous work, an azobenzene-containing
molecular photoswitch termed PhotoETP was designed and
synthesized,[3] based upon an “azologue”[5] of the known GLP-
1R positive allosteric modulator (PAM) 4-(3-(benzyloxy)phenyl)-
2-(ethylsulfinyl)-6-(trifluoro-methyl)pyrimidine (BETP).[6] Notably,
signaling responses to glucagon-like peptide-1 (GLP-1) degra-
dation products could be sculpted by the application of blue
light to induce formation of the trans-isomer.[3] We hypothe-
sized that maximal GLP-1R activation by PAMs requires a mole-
cule with fewer degrees of freedom. As the molecular confor-
mations/interactions required for allosteric activation are large-
ly unknown, we thought that this may be achievable by “pre-
arranging” the molecule.
To produce PAMs with improved activity at the GLP-1R, the
PhotoETP azobenzene diazene unit, which exhibits non-binary
photostationary states,[5] was replaced with a C=C fragment to
introduce a stilbene that displays single isomers. A range of
prearranged molecules were synthesized and tested for their
ability to potentiate GLP-1R signaling responses. In all cases,
compounds incorporating the trans-stilbene outperformed
those with cis-stilbene, in addition to native BETP. As such, we
introduce a photopharmacology-based strategy to direct the
rational design of prearranged PAMs, with broad applicability
to the allosteric regulation of GPCRs involved in health and
disease.
BETP adopts a conformationally free benzyl ether when
bound,[6b] suggesting that, upon activation of the GLP-1R by
orthosteric ligands, it is able to rearrange its shape to fully
engage the allosteric site (Figure 1a). This motion is restricted
by light in PhotoETP, which possesses a photoisomerizable
azobenzene in place of the O-benzyl group (Figure 1b). We
reasoned that replacement of the diazene bridge in PhotoETP
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by a C=C moiety to introduce a stilbene would allow produc-
tion of prearranged PAMs where the cis- and trans-states are
mimicked, but without complications arising from photosta-
tionary states. Stilbenes have the added advantage of being
more drug-like than azobenzenes and may demonstrate better
metabolic stability in terms of double-bond cleavage in the in-
testine and the possible liberation of reactive anilines. Further-
more, BETP uses an ethyl sulfoxide as a leaving group that is
replaced by covalent cysteine attachment on the receptor to
give ethyl sulfenic acid as a leaving group,[6b] and other elec-
trophilic moieties, mainly aryl chlorides and aryl sulfones, have
also been reported to undergo covalent labelling toward the
GLP-1R.[7] We, therefore, wanted to explore whether a methyl
sulfoxide would be tolerated (Figure 1c), as this moiety would:
1) be easier and faster to introduce synthetically from commer-
cially-available substrates, giving cheaper access to PAMs that
target the GLP-1R (Figure 1d); and 2) exhibit methyl sulfenic
acid as an unstable and, therefore, quickly-cleared leaving
group.[8]
To obtain BMTP, that is, the methyl analogue of the lead
compound BETP, as a first model compound, boronic ester
1 was coupled under Suzuki–Miyaura conditions with chloro-
pyrimidine 2 to biaryl 3 in quantitative yield,[9] which was mon-
ooxidized with one equivalent of mCPBA to give BMTP in 94%
yield (Scheme 1a). SMTP and SETP were synthesized in a com-
parable synthetic sequence. Commencing with benzyltriphe-
nylphosphonium bromide (4) and 3-bromobenzaldehyde (5)
that underwent a non-stereoselective Wittig reaction at room
temperature in THF with LiHMDS as base, cis- and trans-bromo
stilbene 6 could be separated through flash column chroma-
tography (FCC) and isolated in 79% overall yield (Scheme 1b).
Single crystals of trans-6 were obtained, which unambiguously
provided the isomeric identity, and this was further confirmed
by the coupling constant 3JHH of the olefinic protons through
1H NMR spectroscopy, being approximately 12 and 16 Hz for
cis- and trans-isomers, respectively. Next, Miyaura coupling
with B2pin2 using PdCl2(dppf) under standard conditions, em-
ploying DMSO as the solvent and KOAc as the base,[10] gave
access to cis- and trans-boronic ester 7 in good yields (78 and
77%, respectively), which were subsequently subjected to
Suzuki–Miyaura Pd cross-coupling with chloropyrimidine 2 to
yield the cis- and trans-thioether precursor 8 in good 76% and
excellent 95% yields, respectively. Progressing towards SMTP,
thioether 6 was monooxidized with one equivalent mCPBA to
give cis- and trans-SMTP in 91 and 89%, respectively.
To progress to the ethyl sulfoxide, thioether 6 was oxidized
with two equivalents of mCPBA to give the corresponding sul-
fone 9 (yield for cis : 95%; trans : 58%), which was subjected to
aromatic substitution with a mixture of ethylsulfide/sodium
thioethanolate to ethyl thioether 10 (cis : 89%; trans : 80%) in
a microwave reactor before final installation of the ethyl sulfox-
ide with one equivalent of mCPBA to obtain cis- and trans-
SETP in 74 and 85% yields, respectively. Lastly, we obtained
a crystal structure of BETP by leaving a DMSO solution open
to the atmosphere for 2 weeks (Scheme 1c), providing atomic
coordinates and showing that BETP is stable for this timeframe
in solution at room temperature and under benchtop light.
Figure 1. Logic and design of prearranged GLP-1R positive allosteric modula-
tors. a) BETP possesses an O-benzyl ether that can freely rotate and adopt
various conformations, occupying a large space, as denoted in the lower
drawing. b) PhotoETP[3] endows GLP-1R with light sensitivity when the azo-
benzene is locked in its active trans-state under blue light illumination (blue
circle), which is interchangeable with UV light to its inactive cis-state (gray
circle). c) Novel stilbene congeners are constantly locked (orange circle) in
their respective state and do not exhibit photostationary states. The func-
tional group for displacement can be a methyl (Me) or ethyl (Et) sulfoxide
(green circle), giving pure trans- and cis-isomers of the prearranged PAMs
SMTP and SETP. d) Schematic representation of GLP-1R activation with
GLP-1(9–36)NH2 in the presence of either trans- or cis-SMTP.
Scheme 1. Synthesis of GLP-1R prearranged PAMs. a) BMTP is obtained after
a two-step synthetic sequence from commercially available boronic ester
1 and chloropyrimidine 2 after Pd cross-coupling and subsequent monooxi-
dation. b) Wittig transformation gives access to trans- and cis-stilbenes that
can be separated by FCC and independently processed towards thioether 8.
trans- and cis-SMTP are obtained as the monooxidized products from 8,
whereas bisoxidation, aromatic substitution, and monooxidation yield the
prearranged positive allosteric modulators trans- and cis-SETP. c) Crystal
structure of BETP.
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The GLP-1R signals primarily through the generation of
cyclic adenosine monophosphate (cAMP).[11] As expected, BETP
potently augmented the cAMP responses to the GLP-1 break-
down product and weak agonist GLP-1(9–36)NH2 (Figure 2a),
but not fully active GLP-1(7–36)NH2 (Figure S1 in the Support-
ing Information). BETP also conferred agonist activity on the
GLP-1R orthosteric antagonist exendin(9–39) (Figure 2b). Al-
though cis-SETP allosterically enhanced cAMP responses, it
was outperformed by trans-SETP, which displayed a threefold
increase in potency as a GLP-1R PAM (as indicated by EC50
values in Table S1). Similar results were seen with BMTP and
SMTP, suggesting that the replacement of ethyl sulfoxide with
its methyl counterpart is well tolerated. Potentiation of GLP-
1(9–36)NH2-induced b-arrestin2 recruitment to the GLP-1R was
also greatest with trans-isoforms (Figure 2c).
PAMs stabilize active receptor conformations and can
behave as agonists, even in the absence of the orthosteric
ligand. When BETP, BMTP, and related prearranged PAMs were
applied in pure agonist mode, cAMP responses were greatest
with trans-diastereomers (Figure 2d). There was, however, no
detectable increase in b-arrestin2 recruitment with any PAM
(Figure S2). We also investigated the ability of these com-
pounds to liberate Ca2+ from internal stores. In the absence of
GLP-1, BMTP induced strong cytosolic Ca2+ rises, more so than
BETP (Figure 2e, f). SETP and SMTP trans-isomers were again
most effective. The effects of BETP and BMTP were likely to be
GLP-1R mediated, as they were almost absent in CHO cells
without GLP-1R overexpression (Figure S3a) and, like
GLP-1(7–36)NH2-induced responses, could be reduced by in-
hibiting G-protein signaling intermediates including Epac2
(ESI09) and phospholipase C (U73122) (Figure S3b–e). Surpris-
ingly, BETP was the only PAM that enhanced the Ca2+ re-
sponse to GLP-1(7–36)NH2 when pre-incubated, as previously
described.[2a] This may reflect depletion of accessible intracellu-
lar Ca2+ stores at a rate dependent on the intrinsic activity of
the PAM (Figure S4).
PAMs increase receptor affinity for extracellular ligand, cou-
pling to intracellular effectors, or both.[12] We employed a time-
resolved Fçrster resonance energy transfer (TR-FRET) approach
to measure ligand-receptor binding in real-time, whereby FITC-
conjugated orthosteric ligand binding to SNAP-GLP-1R self-
labeled with Lumi4-Tb leads to an increase in FRET.[13] For fur-
ther details of this technique, see Section 6.6 in the Supporting
Information. We determined that GLP-1R PAMs substantially
slow down dissociation of GLP-1(7–36)NH2-FITC, increasing res-
idence time[14] (Figure 3a), and also decreasing the rate of asso-
ciation (Figure 3b). The overall effect was to increase binding
affinity of GLP-1(7–36)NH2-FITC approximately fivefold (Fig-
ure 3c). trans-SETP and trans-SMTP increased the residence
time and binding affinity more than their cis-counterparts.
The GLP-1R undergoes extensive internalization after agonist
stimulation, and ongoing cAMP generation by internalized re-
ceptors may play a role in GLP-1R signaling.[16] We hypothe-
sized that the PAMs described here, which unlike peptide li-
gands are membrane-permeating, might access and modulate
the behavior of pre-internalized ligand–receptor complexes
(Figure 3d). After complete GLP-1R internalization with 100 nm
GLP-1(7–36)NH2-FITC (Figure 3e) and washout of remaining ex-
tracellular ligand, a steady reduction in FRET was detected, in-
dicative of ligand–receptor dissociation within endosomes.
However, when BETP, BMTP, and prearranged PAMs were ap-
plied to the cell immediately post-washout, marked reductions
in dissociation from endosomal receptors were observed (Fig-
ure 3 f,g). This effect was most marked with trans-SMTP.
In the present study, we describe a photopharmacology-in-
spired strategy for the rational design of potent GLP-1R PAMs
based upon the allosteric photoswitch PhotoETP.[3] By restrict-
ing degrees of freedom using stilbenes, it could be shown that
compounds prearranged as their trans-isomer were more
potent than other PAMs, including BETP.[6] Such findings likely
reflect the requirement for bound PAMs to undergo fine con-
formational changes at the allosteric site for full activation in
response to orthosteric binding.[6b] Prearrangement may cir-
cumvent this by stabilizing molecule dynamics, allowing PAMs
to adopt an allosteric ’ON’ state when unbound. Moreover, re-
placement of the ethyl sulfoxide moiety with a methyl sulfox-
ide maintained full activity, whilst promoting cheaper and
faster access to PAMs and prearranged PAMs from commercial-
ly available chemicals in high yields. Although the differences
in signaling described here for the prearranged PAMs may
seem small, it should be noted that GLP-1R PAMs allow less
active GLP-1 metabolites to signal at the orthosteric site,[2b]
Figure 2. Prearranged PAMs potently enhance GLP-1R signaling. a) Allosteric
enhancement of GLP-1(9–36)NH2 (“9–36”) cAMP responses (30 min incuba-
tion; n=4) (4-parameter logistic fit shown). b) As for (a), but with exen-
din(9–39) (ex9-39) (n=5). c) Allosteric enhancement of 10 mm GLP-1(9–
36)NH2-induced b-arrestin2 (barr2) recruitment (30 min incubation; n=5).
d) cAMP responses to indicated PAM or prearranged PAM concentration in
the absence of orthosteric ligand (30 min incubation; n=3). e) Cytosolic
Ca2+ responses in Calcium 6 dye-loaded cells, expressed relative to baseline
fluorescent signal (60 min incubation; n=7). f) Area under curve (AUC) de-
termined from (e). *P<0.05, **P<0.01, ***P<0.001; one- or two-way
randomized block ANOVA followed by either Sidak’s or Tukey’s post-hoc
test. Values represent the mean + or  SEM. Except where indicated, PAMs
or prearranged PAMs were applied at 10 mm.
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and resulting small alterations in cell signaling are expected to
translate into large functional differences.
Intriguingly, intracellular Ca2+ fluxes induced by BMTP ex-
ceeded those of BETP, despite equivalent cAMP responses. As
such, the prearranged PAMs may provide useful tools to tease
apart the receptor conformations required for biased signaling
and, more widely, the impact of second messenger preference
on relevant biological endpoints. Although our studies impli-
cated classical GLP-1R pathways, the precise mechanism(s) un-
derlying differences in Ca2+ responses remain unclear. The dif-
ferent leaving groups for BMTP versus BETP (methyl versus
ethyl sulfenate) are potential candidates, as sulfenic acids are
known signaling intermediaries in the context of cysteine
modification.[17] In addition, further studies using recently de-
scribed conformational FRET sensors,[18] or concentration re-
sponses to calculate alpha values,[12,19] are required to unam-
biguously demonstrate the differential actions of the prear-
ranged PAMs at the GLP-1R. It should be noted that the
herein-described prearranged PAMs, as well as BETP, exist as
racemates, and in the future it will be interesting to study the
labeling kinetics of the separate enantiomers before chirality is
lost through covalent modification of GLP-1R.
Finally, we provide the first demonstration that GLP-1R PAMs
can markedly increase agonist residence time, proposed as
a therapeutic strategy to drive sustained responses in vitro and
in vivo.[20] These molecules can also directly access pre-internal-
ized GLP-1Rs to modulate ligand–receptor binding within en-
dosomes. They could, therefore, be used to prolong non-can-
onical cAMP signaling from internalized GLP-1Rs,[16] delineate
effects of membrane versus endosomal GLP-1R signaling, or
study the influence of occupancy on post-endocytic receptor
trafficking.[21]
In summary, we unveil a new class of positive allosteric mod-
ulator PAMs that are prearranged. These compounds perform
better than their compacted stablemates (i.e. those incorporat-
ing a cis-stilbene), as well as benchmark PAM, BETP, and also
display signal bias. Thus, prearranged PAMs provide a template
for the production of newer and more potent allosteric modu-
lators of the GLP-1R, with broad-applicability to GPCR research
and drug discovery.
Experimental Section
Experimental details including synthesis, spectroscopic and spec-
trometric characterization, and biology can be found in the Sup-
porting Information. CCDC 1530565 and 1530566 contain the sup-
plementary crystallographic data for this paper. The data can be
obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/structures.
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COMMUNICATIONS
B. J. Jones, R. Scopelliti, A. Tomas,
S. R. Bloom, D. J. Hodson,*
J. Broichhagen*
&& –&&
Potent Prearranged Positive Allosteric
Modulators of the Glucagon-like
Peptide-1 Receptor
Lock and load: Prearranged positive al-
losteric modulators (PAMs) inspired by
photopharmacology are synthesized
and applied to the glucagon-like pep-
tide-1 receptor (GLP-1R), a class B G pro-
tein-coupled receptor. These novel mol-
ecules outperform the benchmark PAM,
4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-
6-(trifluoro-methyl)pyrimidine (BETP),
and show Ca2+ versus cyclic adenosine
monophosphate (cAMP) signal bias. As
such, prearranged PAMs provide a blue-
print for the generation of more power-
ful and selective PAMs in research and
medicine.
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